Eastman Chemical Company (EMN) has experienced a mixed bag of critical investment perspectives recently. Wells Fargo downgraded the company's stocks to a hold recommendation, echoed by RBC Capital maintaining their buy rating. Meanwhile, Citigroup lifted its price target to $72. The financial performance of Eastman in Q2 and Q3 of 2025 was a miss with weaker demand cited as a key factor leading to a downgraded outlook by S&P heavily influenced by the impact of tariffs. In a positive turn, Eastman announced its 16th consecutive year of dividend increases. Investment adjustments by various entities such as Atlantic Investment Management, JPMorgan Chase & Co., and Invesco Ltd suggest active management of stakes in Eastman. Developments include a new partnership with Huafon Chemical to establish a facility in China, leadership transitions within the board and strategic cost reduction initiatives. However, the stock has been underperforming and is considered oversold with declines in earnings and revenue estimates. Furthermore, recent dividends may not be alluring enough despite their consistency, making Eastman's stocks look inexpensive but not entirely attractive.
Eastman Chemical Company EMN News Analytics from Thu, 24 Apr 2025 07:00:00 GMT to Sat, 20 Dec 2025 12:35:46 GMT -
Rating 1
- Innovation -1
- Information 6
- Rumor -5
